Savara Inc. said Tuesday its marketing application for Molbreevi, a treatment for a rare respiratory disease, was accepted for an accelerated 150-day review by the U.K.’s primary drug regulator.
"The MHRA's acceptance of our application under the new accelerated pathway is a significant milestone for Savara," Matt Pauls, Chair and CEO of Savara, said in a statement.
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) will assess the Marketing Authorisation Application (MAA) for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP). A decision on the application is expected in the fourth quarter of 2026. In the United States, the Food and Drug Administration (FDA) is also reviewing the Biologics License Application (BLA) for Molbreevi under its Priority Review pathway.
The acceptance under an accelerated pathway in a major market like the U.K. significantly de-risks the path to commercialization for Savara's lead product. This news is likely to be a positive driver for Savara's stock (SVRA) as it moves closer to potential approval.
The dual priority reviews in both the U.S. and U.K. highlight the unmet medical need for patients with autoimmune PAP. For investors, the key upcoming catalyst will be the MHRA's decision in Q4 2026, which could pave the way for the company's first commercial sales.
This article is for informational purposes only and does not constitute investment advice.
